Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)

Coma et al. (Mon,) studied this question.

www.synapsesocial.com/papers/68e65665b6db6435875e4e5e — DOI: https://doi.org/10.1136/archdischild-2024-327153

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024· 2024 · 172 citations
2. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024· 2024 · 198 citations
3. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg· 2024 · 129 citations
4. Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three‐year prospective study· 2010 · 210 citations
5. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants· 2020 · 732 citations